drugset / Trial / NCT00406107

Evaluation of Macugen Treatment of Macular Edema Due to Branch Retinal Vein Occlusion

NCT00406107

RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the effect of intravitreal injections of Macugen every 6 weeks for the treatment of macular edema secondary to branch retinal vein occlusion (BRVO). We hypothesize that macular edema secondary to BRVO is mediated by VEGF 165 and that chronic suppression of VEGF 165 will successfully treat BRVO related macular edema.

Timeline

Start
2006-01
Primary completion
2007-12
Completion
2008-04

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator pegaptanib sodium Aptamer 0.3 mg Intravitreal
Comparator pegaptanib sodium Aptamer 1 mg Intravitreal